The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Intratympanic Therapy for Meniere's Disease

Office-based intratympanic injection of gentamicin or steroids for vertigo control in medically refractory Meniere's disease, balancing vestibular ablation with hearing preservation.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our KBB (Kulak Burun Boğaz) department. Book Appointment →

What is Intratympanic Therapy for Meniere's Disease?

Meniere's disease is characterized by endolymphatic hydrops causing the classic tetrad: episodic vertigo (≥20 minutes), fluctuating sensorineural hearing loss (low-frequency initially), tinnitus, and aural fullness. Diagnosis follows AAO-HNS 2015 criteria; MRI with delayed gadolinium can visualize hydrops.

Stepwise treatment ladder: lifestyle (low-sodium diet <1.5 g/day, caffeine/alcohol restriction), pharmacotherapy (betahistine 48 mg/day, hydrochlorothiazide-triamterene), then intratympanic therapy for medically refractory disease (Tumarkin crises, frequent vertigo despite optimal medical therapy for ≥3-6 months).

Intratympanic gentamicin (ITG) is preferred for severe vertigo when functional hearing has already declined; intratympanic steroids (ITS, dexamethasone 4-24 mg/mL or methylprednisolone 40-62.5 mg/mL) are first choice when hearing preservation is paramount. Both delivered via tympanic membrane puncture with patient supine, head turned 30-45° away, allowing 30-45 minutes of medication-mucosa contact.

Symptoms

Disabling vertigo episodes (>2-4 attacks per month despite medical therapy)
Tumarkin otolithic crises (sudden drop attacks without warning)
Progressive sensorineural hearing loss (often low-frequency initially, then flat)
Roaring tinnitus that intensifies during attacks
Aural fullness preceding or during vertigo episodes
Functional impairment (work, driving, fall risk)
Failed medical management trial of ≥3-6 months

Risk Factors

Refractory unilateral Meniere's disease (definite by AAO-HNS criteria)
Functional hearing loss already present (less to lose with gentamicin)
Bilateral disease (caution with gentamicin, consider steroids first)
Active middle ear infection or tympanic membrane perforation (contraindication)
Pregnancy (gentamicin contraindicated)
Patient preference for office-based vs surgical (labyrinthectomy, vestibular nerve section) options
Comorbidities precluding general anesthesia for definitive surgery

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Vertigo episodes >2/month despite optimal medical therapy ≥3 months
  • Tumarkin drop attacks (urgent — fall and injury risk)
  • Progressive hearing loss with persistent vertigo
  • Failed lifestyle and pharmacological intervention
  • Specialized otoneurology consultation for treatment planning

Treatment Methods

01
Pre-treatment evaluation: audiogram, vestibular function tests (videonystagmography, video head-impulse test, vestibular evoked myogenic potentials), MRI to exclude vestibular schwannoma
02
Intratympanic gentamicin protocol options: (1) Low-dose titration (40 mg/mL, single injection, repeat every 4 weeks based on response, max 3-4 injections); (2) Single-shot (40 mg/mL once); (3) Multi-injection weekly. Vertigo control >80%, hearing-loss risk 10-30% (reduced with low-dose titration)
03
Intratympanic steroid protocol: dexamethasone 4-12 mg/mL or methylprednisolone, weekly for 3-4 weeks; vertigo control 60-75% short-term, hearing preservation >95%, but less durable (recurrence common)
04
Procedure technique: topical phenol or EMLA anesthesia of tympanic membrane, supine head turn, 25-G spinal needle puncture in posterior-inferior quadrant, slow medication injection (0.4-0.6 mL), patient remains supine 30-45 minutes, no swallowing
05
Post-injection monitoring: audiogram at baseline, 1 week, 1 month, 3 months; vertigo diary; symptom-specific quality of life (DHI, Meniere's specific QOL)
06
Combination strategies: ITG followed by ITS for hearing protection; ITS as first-line, escalating to ITG if refractory
07
Adjunctive therapy: vestibular rehabilitation 2-4 weeks after vertigo control to address residual imbalance
08
Salvage options if refractory: endolymphatic sac decompression (early disease, hearing-preserving), vestibular nerve section (preserves hearing, requires craniotomy), labyrinthectomy (ablative, only if no useful hearing)
09
Bilateral disease: avoid gentamicin (bilateral vestibular loss = oscillopsia), prefer ITS, consider sequential treatment with strict monitoring
10
Long-term outcomes: 75-85% vertigo control at 2 years with ITG; 5-10% require revision injection; chronic imbalance in 20% requires ongoing vestibular rehabilitation

Which Department to Visit?

You can visit our KBB (Kulak Burun Boğaz) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About KBB (Kulak Burun Boğaz) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.